Jubilant Ingrevia Share News - Latest Updates, Live News & More

Latest news about Jubilant Ingrevia

Jubilant Ingrevia Reports Strong Q2 FY26 Performance with 7% Revenue Growth and Expanding CDMO Pipeline 3 days ago

Jubilant Ingrevia achieved its highest quarterly revenue in 10 quarters, reaching INR 1,121.00 crore, a 7% year-on-year growth. EBITDA grew by 8% to INR 146.00 crore, while profit after tax increased by 18% to INR 70.00 crore. The Specialty Chemicals segment saw 12% revenue growth with 26% EBITDA margins. The company's CDMO business added over 10 new molecules with INR 1,200.00 crore peak annual revenue potential and secured a $300.00 million contract over 5 years. Jubilant Ingrevia also made progress in sustainability efforts, increasing its renewable power share to 28% and reducing energy costs by 16%.

Jubilant Ingrevia Targets 18 New Product Launches in FY'26, Eyes INR 2,000 Crore EBITDA by FY'30 6 days ago

Jubilant Ingrevia Sets Revenue Target of ₹7,500-8,000 Crore by FY27, Anticipates Acetyls Recovery 7 days ago

Jubilant Ingrevia Reports Robust Q2 Performance with 17.7% Net Profit Growth 7 days ago

Jubilant Ingrevia Issues Rs. 50 Crore Commercial Papers with 57-Day Tenure Sep 25, 2025

More news about Jubilant Ingrevia

02Sept 25

Jubilant Ingrevia Shows Signs of Recovery Amid Global Market Shifts

Jubilant Ingrevia, a leading chemical and nutrition products manufacturer, is experiencing a recovery with a 5% share gain since mid-August. The company's domestic focus (56% of revenue) mitigates international tariff impacts. A 120% EU anti-dumping duty on Chinese choline chloride benefits Jubilant, which holds over 50% market share in India. The company plans a ₹600 crore capex for FY26, expanding capacity by 15-20% at existing plants and constructing a new multi-purpose plant. Management reports volume increases in key sectors after weak performance. A cost optimization program aims for ₹100 crore annual savings by FY26. Equirus Securities forecasts 34% annual growth in operating margin between FY25 and FY28.

11Aug 25

Jubilant Ingrevia Issues ₹500 Million in Commercial Papers

Jubilant Ingrevia Limited has issued commercial papers worth ₹500 million with a 45-day tenure. The CPs, allotted on August 11, 2025, will mature on September 25, 2025, carrying a 5.95% per annum coupon rate. This issuance is part of the company's ₹6 billion CP program, with the current outstanding amount at ₹1.7 billion. The unsecured papers will be listed on the National Stock Exchange of India Limited.

31Jul 25

Jubilant Ingrevia Reports Strong Q1 FY26 Results, Appoints New Director

Jubilant Ingrevia Limited announced robust Q1 FY26 results with consolidated revenue of ₹1,037.95 crore, up 1.3% YoY. EBITDA increased by 29% to ₹153.00 crore, and net profit grew by 54% to ₹75.10 crore. The Specialty Chemicals segment was the top performer, contributing 46% to total revenue and 76% to overall EBITDA. The company appointed Ms. Aashti Bhartia as an Additional Non-Executive Director and made its third investment in O2 Renewable Energy XVIII Private Limited. Management expressed confidence in continued growth, driven by advancements in Specialty Chemicals and Nutrition businesses.

31Jul 25

Jubilant Ingrevia Reports 54% Surge in Q1 Profit, Announces Board Changes

Jubilant Ingrevia Limited reported a 54% year-over-year increase in Q1 standalone net profit to Rs 75.00 crore. Total revenue from operations grew 1% to Rs 1,038.00 crore. EBITDA rose 29% to Rs 153.00 crore, with margin improving to 15%. Specialty Chemicals segment remained strong, contributing 46% to revenue and 76% to EBITDA. The company appointed Ms. Aashti Bhartia as Additional Non-Executive Director, while Mr. Arjun Shanker Bhartia stepped down. Jubilant Ingrevia also invested in renewable energy and anticipates delivering a significant CDMO order in early 2026.

31Jul 25

Jubilant Ingrevia Reports Quarterly Results with Investment in Renewable Energy

Jubilant Ingrevia Limited has announced its financial results for Q1 ending June 30. The company reported consolidated revenue of ₹103,795.00 lakhs and net profit of ₹7,510.00 lakhs. The basic EPS stood at ₹4.75. Jubilant Ingrevia made its third tranche of investment in O2 Renewable Energy XVIII Private Limited for solar and wind power generation. The company also has outstanding commercial papers worth ₹15,000.00 lakhs listed on NSE, maturing in July.

18Jul 25

Jubilant Ingrevia Issues ₹50 Crore in Commercial Papers

Jubilant Ingrevia Limited has announced the issuance of Commercial Papers worth ₹50 crore with a 60-day tenure. The CPs, allotted on July 18, 2025, will mature on September 16, 2025, carrying a coupon rate of 5.95% per annum. This unsecured issuance is part of a larger ₹600 crore CP program approved by the company's Finance Committee. With this addition, Jubilant Ingrevia's total outstanding Commercial Papers now stand at ₹200 crore.

30Jun 25

Jubilant Ingrevia in Focus as Government Launches Anti-Dumping Probe on Methyl Acetoacetate Imports

The Indian government has initiated an anti-dumping investigation into Methyl Acetoacetate imports from Switzerland. This probe could impact Jubilant Ingrevia, a key player in the chemical industry. The investigation aims to determine if these imports are being sold at unfairly low prices, potentially harming domestic producers. Possible outcomes include the imposition of anti-dumping duties, market rebalancing, and price adjustments in the domestic market. This move highlights the government's efforts to protect domestic industries from unfair trade practices and could have broader implications for India's specialty chemicals sector.

06Jun 25

Jubilant Ingrevia Raises ₹1 Billion Through Commercial Paper Issuance

Jubilant Ingrevia, a leading specialty chemicals company, has successfully raised ₹1 billion (approximately $12.00 million) through the issuance of commercial papers. This short-term debt instrument is typically used for immediate funding needs with maturities up to one year. The move demonstrates Jubilant Ingrevia's proactive approach to managing short-term financing needs and its ability to access cost-effective funding sources.

14May 25

Jubilant Ingrevia Eyes Growth in Specialty Chemicals and Health Solutions

Jubilant Ingrevia announces strategic focus on specialty chemicals and nutrition and health solutions for future growth. The company plans to capitalize on increasing demand in these sectors, develop new products, and expand market presence. Additionally, Jubilant Ingrevia will implement cost management initiatives to streamline operations and improve profitability. While specific financial figures are not provided, management expresses confidence in sustained growth based on these strategic initiatives.

13May 25

Jubilant Ingrevia Reports Robust Q4 FY25 Results with Significant Profit Growth

Jubilant Ingrevia reported a consolidated net profit of ₹74.05 crore in Q4 FY25, up 153.16% from ₹29.25 crore in Q4 FY24. Total income remained stable at ₹1,059.62 crore. For the full fiscal year 2025, the company posted a net profit of ₹251.17 crore and total income of ₹4,215.43 crore.

25Apr 25

Jubilant Ingrevia Advances in Renewable Energy Venture, Acquires Partial Stake in O2 Renewable Energy XVIII

Jubilant Ingrevia has acquired a partial stake in O2 Renewable Energy XVIII Private Limited, comprising 3,602,875 equity shares and 61,346 Compulsorily Convertible Debentures. This acquisition, part of a planned 28% stake, aims to access 6.41 MW of renewable power for its manufacturing facilities in Uttar Pradesh and Gujarat. The remaining stake acquisition is expected to be completed by June 2025. This move aligns with the company's sustainability goals and green energy requirements.